Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Syros Pharmaceuticals Inc. (SYRS)

6.28   -0.41 (-6.13%) 02-25 16:00
Open: 6.71 Pre. Close: 6.69
High: 6.75 Low: 6.25
Volume: 147,405 Market Cap: 267M
Syros Pharmaceuticals Inc is a biopharmaceutical company pioneering an understanding of the region of the genome controlling the activation and repression of genes.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.753 - 6.798 6.798 - 6.836
Low: 6.168 - 6.209 6.209 - 6.244
Close: 6.219 - 6.287 6.287 - 6.343

Technical analysis

as of: 2020-02-25 4:33:44 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 8.95     One year: 9.97
Support: Support1: 6.25    Support2: 5.20
Resistance: Resistance1: 7.67    Resistance2: 8.54
Pivot: 7.34
Moving Average: MA(5): 6.96     MA(20): 7.27
MA(100): 6.59     MA(250): 7.56
MACD: MACD(12,26): -0.10     Signal(9): 0.03
Stochastic oscillator: %K(14,3): 17.46     %D(3): 31.51
RSI: RSI(14): 37.16
52-week: High: 11.93  Low: 4.45  Change(%): -9.2
Average Vol(K): 3-Month: 41121  10-Days: 14870

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
SYRS has closed below the lower band by 14.3%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 37.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Syros to Present at Upcoming Investor Conferences in March
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences: Cowen and Company 40th Annual Health Care Conference in Boston, MA on Monday, March 2, 2020 at 4:50 p.m. ET. Oppenheimer 30th Annual Healthcare Conference in New York, NY on Wednesday March 18, 2020 at 10:55 a.m. ET. Live webcasts of the presentations will be availabl

Syros Announces $60 Million Loan Facility with Oxford Finance LLC
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of a $60 million senior secured loan facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare service companies. “The initial $20 million tranche of this financing extends our expected cash runway into 2022, beyond key planned clinical data readouts for SY-1425 an

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 42.44
Shares Float (M) 30.91
% Held by Insiders 9.80
% Held by Institutions 87.82
Shares Short (K) 2340
Shares Short P. Month (K)

Stock Financials

EPS -1.950
Book Value (p.s.) 2.230
PEG Ratio
Profit Margin
Operating Margin -3218.33
Return on Assets (ttm) -36.0
Return on Equity (ttm) -77.9
Qtrly Rev. Growth 35.4
Gross Profit (p.s.) 0.048
Sales Per Share
EBITDA (p.s.) -1.742
Qtrly Earnings Growth
Operating Cash Flow (M) -63.46
Levered Free Cash Flow (M) -43.27

Stock Valuations

P/E -3.22
P/E Growth Ratio -0.06
P/BV 2.82
P/S 104.66
P/CF -4.20

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.